X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA JUBILANT LIFE SCIENCES AUROBINDO PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 13.6 12.2 111.1% View Chart
P/BV x 3.0 1.7 175.6% View Chart
Dividend Yield % 0.4 0.7 61.0%  

Financials

 AUROBINDO PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
JUBILANT LIFE SCIENCES
Mar-18
AUROBINDO PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs8091,039 77.9%   
Low Rs504600 84.0%   
Sales per share (Unadj.) Rs281.1482.6 58.2%  
Earnings per share (Unadj.) Rs41.440.7 101.6%  
Cash flow per share (Unadj.) Rs50.967.4 75.5%  
Dividends per share (Unadj.) Rs2.503.00 83.3%  
Dividend yield (eoy) %0.40.4 104.0%  
Book value per share (Unadj.) Rs199.4262.3 76.0%  
Shares outstanding (eoy) m585.88155.79 376.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.31.7 137.5%   
Avg P/E ratio x15.920.1 78.9%  
P/CF ratio (eoy) x12.912.2 106.1%  
Price / Book Value ratio x3.33.1 105.4%  
Dividend payout %6.07.4 82.1%   
Avg Mkt Cap Rs m384,630127,670 301.3%   
No. of employees `00017.32.4 711.5%   
Total wages/salary Rs m21,30815,559 137.0%   
Avg. sales/employee Rs Th9,500.730,861.4 30.8%   
Avg. wages/employee Rs Th1,229.46,387.0 19.2%   
Avg. net profit/employee Rs Th1,397.92,604.4 53.7%   
INCOME DATA
Net Sales Rs m164,66675,178 219.0%  
Other income Rs m1,020400 254.8%   
Total revenues Rs m165,68675,579 219.2%   
Gross profit Rs m37,71815,184 248.4%  
Depreciation Rs m5,5804,151 134.4%   
Interest Rs m7772,843 27.3%   
Profit before tax Rs m32,3808,591 376.9%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1832,247 364.2%   
Profit after tax Rs m24,2296,344 381.9%  
Gross profit margin %22.920.2 113.4%  
Effective tax rate %25.326.2 96.6%   
Net profit margin %14.78.4 174.4%  
BALANCE SHEET DATA
Current assets Rs m121,87831,898 382.1%   
Current liabilities Rs m86,80620,047 433.0%   
Net working cap to sales %21.315.8 135.1%  
Current ratio x1.41.6 88.2%  
Inventory Days Days13068 192.2%  
Debtors Days Days6855 124.5%  
Net fixed assets Rs m81,03760,715 133.5%   
Share capital Rs m586156 376.1%   
"Free" reserves Rs m116,21840,710 285.5%   
Net worth Rs m116,80440,865 285.8%   
Long term debt Rs m4,51230,478 14.8%   
Total assets Rs m211,05296,176 219.4%  
Interest coverage x42.74.0 1,060.8%   
Debt to equity ratio x00.7 5.2%  
Sales to assets ratio x0.80.8 99.8%   
Return on assets %11.89.6 124.0%  
Return on equity %20.715.5 133.6%  
Return on capital %27.416.0 170.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72714,402 560.5%   
Fx outflow Rs m34,70012,044 288.1%   
Net fx Rs m46,0272,358 1,951.9%   
CASH FLOW
From Operations Rs m19,54813,032 150.0%  
From Investments Rs m-19,570-6,177 316.8%  
From Financial Activity Rs m8,642-9,011 -95.9%  
Net Cashflow Rs m8,922-2,123 -420.3%  

Share Holding

Indian Promoters % 54.1 45.6 118.6%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 8.0 8.7 91.4%  
FIIs % 27.7 21.2 130.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 21.1 48.3%  
Shareholders   69,601 23,815 292.3%  
Pledged promoter(s) holding % 8.6 15.9 54.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CIPLA  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 267 Points Lower; Metal and Capital Goods Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

More Views on News

Most Popular

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 21, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS